Nuvectis Pharma, Inc. NVCT
We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements.
We were incorporated in July 2020 under the laws of the State of Delaware under the name Centry Pharma, Inc., and changed our name to Nuvectis Pharma, Inc. in July 2021. Our office is located at 1 Bridge Plaza, 2nd Floor, Fort Lee, NJ 07024, and our telephone number is (201) 614-3150.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $18.2M | $12.9M | $15.4M | $13.2M | $9.5M | — |
| SG&A | $9.4M | $6.9M | $7.5M | $6.0M | $3.3M | — |
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M | -$12.9M | — |
| Net income | -$26.4M | -$19.0M | -$22.3M | -$19.1M | -$12.9M | — |
| EPS, basic | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 | — |
| EPS, diluted | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 | — |
| Shares, diluted (wtd. avg.) | $21.8M | $17.1M | $15.6M | $12.7M | $4.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M | — |
| Total current assets | $31.7M | $18.6M | $19.2M | $20.4M | $5.8M | — |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M | — |
| Accounts payable | $6.3M | $2.5M | $2.8M | $2.9M | $1.1M | — |
| Total current liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M | — |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M | — |
| Retained earnings | -$99.7M | -$73.2M | -$54.2M | -$32.0M | -$12.9M | — |
| Total equity | $18.4M | $9.7M | $12.2M | $14.2M | -$11.0M | -$10.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$16.0M | -$12.2M | -$16.0M | -$13.6M | -$9.5M | — |
| Stock-based compensation | $6.0M | $4.9M | $4.7M | $1.7M | $1.9M | — |
| Investing cash flow | — | $0 | $0 | $0 | — | — |
| Financing cash flow | $29.1M | $11.7M | $15.1M | $27.8M | $15.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-013044.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |